ACT CANDESARTAN TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

CANDESARTAN CILEXETIL

제공처:

ACTAVIS PHARMA COMPANY

ATC 코드:

C09CA06

INN (국제 이름):

CANDESARTAN

복용량:

4MG

약제 형태:

TABLET

구성:

CANDESARTAN CILEXETIL 4MG

관리 경로:

ORAL

패키지 단위:

30/100/500

처방전 유형:

Prescription

치료 영역:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

제품 요약:

Active ingredient group (AIG) number: 0135220001; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2019-08-13

제품 특성 요약

_ _
_ACT CANDESARTAN Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ Page 1 of 35 _
_ _
_ _
_ _
_ _
_ _
PRODUCT MONOGRAPH
Pr
ACT CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 6J5
Date of Revision:
May 3, 2016
Submission Control No: 194118
_ _
_ACT CANDESARTAN Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ Page 2 of 35 _
_ _
_ _
_ _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
...............................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND STABILITY
.........................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 22
PART II: SCIENTIFIC INFORMATION
...............................................................................
23
PHARMACEUTICAL INFORMATION
.........................................................................
23
CLINICAL TRIALS
............